|
|
Reference
|
|
  
|
Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., Ramírez, C., Cavallari, U., Trabetti, E., Sabaté, M., Hernández, R., Moreno, R., Escaned, J., Alfonso, F., Bañuelos, C., Costa, M.A., Bass, T.A. (2006) Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arteriosclerosis, thrombosis, and vascular biology, 26(8): 1895-900
|
|
1
|
Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., Alfonso, F., Macaya, C., Bass, T.A., Costa, M.A. (2007) Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. Journal of the American College of Cardiology, 49(14): 1505-16
|
|
|
Brophy, J.M., Babapulle, M.N., Costa, V., Rinfret, S. (2006) A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. American heart journal, 152(2): 263-9
|
|
7 
|
Cannon, C.P., Braunwald, E., McCabe, C.H., Rader, D.J., Rouleau, J.L., Belder, R., Joyal, S.V., Hill, K.A., Pfeffer, M.A., Skene, A.M. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 350(15): 1495-504
|
|
|
Clarke, T.A., Waskell, L.A. (2003) The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug metabolism and disposition: the biological fate of chemicals, 31(1): 53-9
|
|
2
|
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., Bernini, F. (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther, 84(3): 413-28
|
|
|
Ding, Z., Kim, S., Dorsam, R.T., Jin, J., Kunapuli, S.P. (2003) Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood, 101(10): 3908-14
|
|
|
Djukanovic, N., Todorovic, Z., Obradovic, S., Njegomirovic, S., Zamaklar-Trifunovic, D., Protić, D., Ostojic, M. (2014) Clopidogrel cessation triggers aspirin rebound in patients with coronary stent. Journal of clinical pharmacy and therapeutics, 39(1): 69-72
|
|
2 
|
Djukanovic, N., Todorovic, Z.M., Grdinic, A., Vojvodic, D., Prostran, M.S., Ostojic, M.C. (2008) Thienopyridine resistance among patients undergoing intracoronary stent implantation and treated with dual antiplatelet therapy: Assessment of some modifying factors. Journal of Pharmacological Sciences, vol. 107, br. 4, str. 451-455
|
|
|
Djukanovic, N., Todorovic, Z., Obradovic, S., Zamaklar-Trifunovic, D., Njegomirovic, S., Milic, N.M., Prostran, M., Ostojic, M. (2011) Abrupt cessation of one-year clopidogrel treatment is not associated with thrombotic events. Journal of pharmacological sciences, 117(1): 12-8
|
|
|
Đukanović, N., Todorović, Z., Njegomirović, S., Ostojić, M., Prostran, M. (2012) Advantages and limitations of clopidogrel response testing methods. Vojnosanitetski pregled, vol. 69, br. 4, str. 353-357
|
|
|
Geisler, T., Zürn, C., Paterok, M., Göhring-Frischholz, K., Bigalke, B., Stellos, K., Seizer, P., Kraemer, B.F., Dippon, J., May, A.E., Herdeg, C., Gawaz, M. (2008) Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. European heart journal, 29(13): 1635-43
|
|
|
Grdinic, A., Vojvodic, D., Djukanovic, N., Colic, M., Grdinic, A.G., Ignjatovic, V., Majstorovic, I., Ilic, V., Magic, Z., Obradovic, S., Ostojic, M., Dolijanovic, S.P. (2011) PCI and clopidogrel: antiplatelet responsiveness and patient characteristics. Acta cardiologica, 66(3): 333-40
|
|
1
|
Grdinić, A., Vojvodić, D., Ilić, V., Magić, Z., Đukanović, N., Radovanović, M., Miljić, P., Obradović, S., Majstorović, I., Cikota, B., Ostojić, M. (2009) The importance of tests applied to evaluate the effectiveness of antiplatelet therapy in patients with recurrent coronary stent thrombosis. Vojnosanitetski pregled, vol. 66, br. 4, str. 328-332
|
|
|
Hamm, C.W., Bassand, J.-P., Agewall, S., Bax, J., Boersma, E., Bueno, H., Caso, P., Dudek, D., Gielen, S., Huber, K., Ohman, M., Petrie, M.C., Sonntag, F., Uva, M.S., Storey, R.F., Wijns, W., Zahger, D., Bax, J.J., Auricchio, A., Baumgartne (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment ele. European Heart Journal, 32(23): 2999-3054
|
|
2
|
Jones, P.H., Davidson, M.H., Stein, E.A., Bays, H.E., McKenney, J.M., Miller, E., Cain, V.A., Blasetto, J.W., STELLAR.Study Group (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol, 92(2): 152-60
|
|
1
|
Kazui, M., Nishiya, Y., Ishizuka, T., Hagihara, K., Farid, N.A., Okazaki, O., Ikeda, T., Kurihara, A. (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug metabolism and disposition: the biological fate of chemicals, 38(1): 92-9
|
|
|
Kushner, F.G., Hand, M., Smith, S.C., King, S.B., Anderson, J.L., Antman, E.M., Bailey, S.R., Bates, E.R., Blankenship, J.C., Casey, D.E., Green, L.A., Hochman, J.S., Jacobs, A.K., Krumholz, H.M., Morrison, D.A., Ornato, J.P., Pearle, D.L., Peterson, E.D. (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005. Circulation, 120(22): 2271-2306
|
|
1
|
Lau, W.C., Waskell, L.A., Watkins, P.B., Neer, C.J., Horowitz, K., Hopp, A.S., Tait, A.R., Carville, D.G.M., Guyer, K.E., Bates, E.R. (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation, 107(1): 32-7
|
|
|
Lau, W.C., Gurbel, P.A., Watkins, P.B., Neer, C.J., Hopp, A.S., Carville, D.G.M., Guyer, K.E., Tait, A.R., Bates, E.R. (2004) Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation, 109(2): 166-71
|
|
|
Lotfi, A., Schweiger, M.J., Giugliano, G.R., Murphy, S.A., Cannon, C.P. (2008) High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients-A Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 2. American Heart Journal, 155(5): 954-958
|
|
|
Mach, F., Senouf, D., Fontana, P., Boehlen, F., Reber, G., Daali, Y., de Moerloose, P., Sigwart, U. (2005) Not all statins interfere with clopidogrel during antiplatelet therapy. European journal of clinical investigation, 35(8): 476-81
|
|
|
Neubauer, H., Günesdogan, B., Hanefeld, C., Spiecker, M., Mügge, A. (2003) Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study. European heart journal, 24(19): 1744-9
|
|
2
|
Nissen, S.E., Tuzcu, E., Schoenhagen, P., Brown, B., Ganz, P., Vogel, R.A., Crowe, T., Howard, G., Cooper, C.J., Brodie, B., Grines, C.L., DeMaria, A.N., REVERSAL.Investigators (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA, 291(9): 1071-80
|
|
|
Obradovic, S., Djukanovic, N., Todorovic, Z., Markovic, I., Zamaklar-Trifunovic, D., Protic, D., Ostojic, M. (2015) Men with lower HDL cholesterol levels have significant increment of soluble CD40 ligand and high-sensitivity CRP levels following the cessation of long-term clopidogrel therapy. Journal of atherosclerosis and thrombosis, 22(3): 284-92
|
|
|
Park, Y., Jeong, Y., Tantry, U.S., Ahn, J.H., Kwon, T.J., Park, J.R., Hwang, S., Gho, E., Bliden, K.P., Kwak, C.H., Hwang, J., Kim, S., Gurbel, P.A. (2012) Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. European heart journal, 33(17): 2151-62
|
|
|
Pelliccia, F., Rosano, G., Marazzi, G., Vitale, C., Spoletini, I., Franzoni, F., Speziale, G., Polacco, M., Greco, C., Gaudio, C. (2014) Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy. Circulation journal, 78(3): 679-84
|
|
|
Pereillo, J., Maftouh, M., Andrieu, A., Uzabiaga, M., Fedeli, O., Savi, P., Pascal, M., Herbert, J., Maffrand, J., Picard, C. (2002) Structure and stereochemistry of the active metabolite of clopidogrel. Drug metabolism and disposition: the biological fate of chemicals, 30(11): 1288-95
|
|
|
Piorkowski, M., Weikert, U., Schwimmbeck, P., Martus, P., Schultheiss, H., Rauch, U. (2004) ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. Thrombosis and haemostasis, 92(3): 614-20
|
|
|
Sangkuhl, K., Klein, T.E., Altman, R.B. (2010) Clopidogrel pathway. Pharmacogenetics and Genomics, 20(7):463-5
|
|
|
Saw, J. (2003) Lack of Adverse Clopidogrel-Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial. Circulation, 108(8): 921-924
|
|
1
|
Saw, J., Brennan, D.M., Steinhubl, S.R., Bhatt, D.L., Mak, K., Fox, K., Topol, E.J. (2007) Lack of Evidence of a Clopidogrel-Statin Interaction in the CHARISMA Trial. Journal of the American College of Cardiology, 50(4): 291-295
|
|
|
Serebruany, V.L., Midei, M.G., Malinin, A.I., Oshrine, B.R., Lowry, D.R., Sane, D.C., Tanguay, J., Steinhubl, S.R., Berger, P.B., o`Connor Christopher, M., Hennekens, C.H. (2004) Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel. Archives of Internal Medicine, 164(18): 2051
|
|
|
Todorović, Z., Mugosa, S., Djordjevic, N., Djukanovic, N., Protic, D., Bukumiric, Z., Radosavljevic, I., Boskovic, A. (2016) Factors affecting the development of adverse drug reactions to β-blockers in hospitalized cardiac patient population. Patient Preference and Adherence, Volume 10: 1461-1469
|
|
|
Trenk, D., Hochholzer, W., Frundi, D., Stratz, C., Valina, C.M., Bestehorn, H., Büttner, H.J., Neumann, F. (2008) Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thrombosis and haemostasis, 99(1): 174-81
|
|
1
|
Vinholt, P., Poulsen, T.S., Korsholm, L., Kristensen, S.R., Hallas, J., Damkier, P., Mickley, H. (2005) The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thrombosis and haemostasis, 94(2): 438-43
|
|
|
White, C. (2002) A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. Journal of clinical pharmacology, 42(9): 963-70
|
|
|
Wienbergen, H., Gitt, A.K., Schiele, R., Juenger, C., Heer, T., Meisenzahl, C., Limbourg, P., Bossaller, C., Senges, J. (2003) Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. American Journal of Cardiology, 92(3): 285-288
|
|
|
Wijns, W., Kolh, P., Danchin, N., di Mario, C., Falk, V., Folliguet, T., Garg, S., Huber, K., James, S., Knuuti, J., Lopez-Sendon, J., Marco, J. (2010) Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 31(20): 2501-2555
|
|
|
Williams, D., Feely, J. (2002) Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clinical pharmacokinetics, 41(5): 343-70
|
|
|
|
|